99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer

NCT05622240 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: 99mTc-MIRC213

Sponsor

Peking Union Medical College Hospital